Pharmaceuticals · NYSE: ABBV
AbbVie earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 3 Feb 2027
Latest: Q3 2026
AbbVie reported third-quarter net revenues of $17.404 billion, an increase of 10.3 percent on a reported basis, with diluted EPS of $2.37 on a GAAP basis and adjusted diluted EPS of $3.82.
AbbVie's third-quarter net revenues were $17.404 billion, up 10.3 percent on a reported basis. Immunology led growth at $9.165 billion, with Skyrizi at $5.776 billion and Rinvoq at $2.706 billion. Neuroscience rose 19.4 percent. Humira, Imbruvica and aesthetics were weaker. GAAP diluted EPS was $2.37 and adjusted diluted EPS was $3.82. A year ago, acquired IPR&D costs weighed far more heavily on both measures. AbbVie also completed its Apogee Therapeutics acquisition.
Quarters
KPI history
Data
| Q4 2024 | $15.1B |
| Q1 2025 | $13.3B |
| Q2 2025 | $15.4B |
| Q3 2025 | $15.8B |
| Q4 2025 | $16.6B |
| Q1 2026 | $15.0B |
| Q2 2026 | $17.0B |
| Q3 2026 | $17.4B |
Data
| Q4 2024 | -$0.02 |
| Q1 2025 | $0.72 |
| Q2 2025 | $0.52 |
| Q3 2025 | $0.10 |
| Q4 2025 | $1.02 |
| Q1 2026 | $0.39 |
| Q2 2026 | $2.03 |
| Q3 2026 | $2.37 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -9.9% |
| Q1 2025 | 28.0% |
| Q2 2025 | 31.7% |
| Q3 2025 | 12.1% |
| Q4 2025 | 27.3% |
| Q1 2026 | 26.6% |
| Q2 2026 | 37.9% |
| Q3 2026 | 36.0% |
Data
| Q4 2024 | $6.8B |
| Q1 2025 | $1.4B |
| Q2 2025 | $4.9B |
| Q3 2025 | $6.6B |
| Q4 2025 | $4.9B |
| Q1 2026 | $3.6B |
| Q2 2026 | $3.1B |
| Q3 2026 | $7.3B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.1B | $13.3B | $15.4B | $15.8B | $16.6B | $15.0B | $17.0B | $17.4B |
| Gross margin | 70.9% | — | — | — | 72.6% | — | — | — |
| Operating income | -$1.5Bd | $3.7B | $4.9B | $1.9B | $4.5Bd | $4.0B | $6.4B | $6.3B |
| Operating margin | -9.9% | 28.0% | 31.7% | 12.1% | 27.3% | 26.6% | 37.9% | 36.0% |
| Net income | -$22.0M | $1.3B | $938.0M | $186.0M | $1.8B | $695.0M | $3.6B | $4.2B |
| Diluted EPS | -$0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 | $2.03 | $2.37 |
| Operating cash flow | $7.0Bd | $1.6B | $5.2Bd | $7.0Bd | $5.2Bd | $3.8B | $3.4Bd | $7.6Bd |
| Capital expenditure | $291.0Md | $235.0M | $269.0Md | $381.0Md | $329.0Md | $265.0M | $322.0Md | $301.0Md |
| Free cash flow | $6.8B | $1.4B | $4.9B | $6.6B | $4.9B | $3.6B | $3.1B | $7.3B |
| R&D expense | $6.8Bd | $2.1B | $2.1B | $2.3B | $2.6Bd | $2.5B | $2.3B | $2.6B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-Q and 10-K filings
- 3 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 3 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 8 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 20 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 4 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 4 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 9 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 14 Feb 202510-K for the period ended 31 Dec 2024SEC ↗